Phathom Pharmaceuticals Inc Dossier - Source-backed chat

Phathom Pharmaceuticals Inc

PHATNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.65

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.08Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $572.8M

Enterprise Value $554.9M

Shares Outstanding 83.6M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Phathom Pharmaceuticals is transitioning from a development-stage biotech to a high-growth commercial entity, driven by the rapid market adoption of its flagship product, VOQUEZNA (vonoprazan). Following a strategic sales force realignment in late 2025, the company is demonstrating strong commercial execution, with Q1 2026 net revenues doubling year-over-year to $58.3 million. Backed by a robust gross margin of approximately 80% and disciplined expense management, Phathom is on a clear path to achieving operating profitability by Q3 2026 and positive cash flow in 2027. The significant valuation gap between its current trading price and consensus analyst targets presents an attractive entry point for investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$21.50

High · most bullish analyst$29.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial uptake slows due to intense competition from established proton pump inhibitors (PPIs) and seasonal health plan access dynamics. Gross-to-net discounts widen beyond the guided 55% to 59% range, compressing margins. Delays in clinical readouts or failure to achieve operating profitability by Q3 2026 forces dilutive capital raises.

Base CaseCentral scenario

The company successfully executes its commercial strategy for VOQUEZNA, meeting its FY 2026 revenue guidance of $320 million to $345 million. Operating profitability is achieved in Q3 2026 as guided, and cash burn continues to narrow, supported by the $180.9 million cash balance and disciplined spending. The Phase 2 EoE trial delivers positive topline results in late 2026, expanding the addressable market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with Q1 2026 net revenues growing 104% year-over-year to $58.3 million.
Clear path to operating profitability by Q3 2026 and positive cash flow in 2027.
High-margin profile with gross margins guided at approximately 80% for FY 2026.
Significant market opportunity in acid-related GI disorders with VOQUEZNA positioned as a first-in-class PCAB.

Key Investment Risks

Commercial execution risk and reliance on a single primary asset (vonoprazan).
Pricing and reimbursement pressures, with gross-to-net discounts guided at a high 55% to 59%.
Competition from low-cost generic proton pump inhibitors (PPIs).
Historical cash burn and accumulated deficit, though mitigated by recent capital raises and debt restructuring.

Thesis Invalidation Triggers

Failure to achieve operating profitability (excluding stock-based compensation) by Q3 2026.
A significant drop in the insurance coverage rate of VOQUEZNA prescriptions below 60%.
Negative or inconclusive topline results from the Phase 2 pHalcon-EoE-201 trial.
Gross-to-net discounts consistently exceeding 60%, severely impacting net revenue realization.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.